Check-Cap
RELATED CONTENT
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through detection of precancerous polyps, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested C-Scan, a preparation-free capsule, at the New York University School of Medicine.
April 15, 2019 
Check-Cap Ltd. recently announced the enrollment of the first patient in its multi-center study of the C-Scan system in support of its CE Mark submission.
January 31, 2017
Check-Cap Ltd. announced additional clinical data was recently presented on its ingestible capsule for preparation-free, minimally-invasive colorectal cancer screening. The research was presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, Oct. 14-19 in Las Vegas, and at the United European Gastroenterology Week (UEGW), Oct. 15-19 in Vienna.
October 27, 2016
Check-Cap Ltd. announced that preliminary data from pre-clinical and clinical studies of its ingestible capsule for preparation-free colorectal cancer screening were discussed during Digestive Disease Week (DDW) 2016, May 21-24 in San Diego.
May 26, 2016
Based on its recent analysis of the wireless capsule endoscopes market, Frost & Sullivan presented Check-Cap Ltd. with the 2013 European Frost & Sullivan Award for New Product Innovation Leadership.
November 21, 2013
February 7, 2012 — GE Capital and GE Healthcare announced an investment in Check-Cap Ltd., developer of an ingestible imaging capsule that may help detect colorectal cancer.
February 08, 2012